On October 11, 2022 Jinxi Jemincare, a China pharma formed in 1999, reported that out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement (Press release, Shanghai Jemincare Pharmaceutical, OCT 11, 2022, View Source [SID1234621924]). JMKX002992 is being developed to treat prostate cancer patients who have developed resistance to current therapies. The oral small molecule candidate, which was developed in Shanghai Jemincare’s 500-scientist R&D center, is currently in preclinical testing. Jemincare will receive $60 million upfront and the rest in milestones, plus royalties. Roche said the agreement was the first global in-licensing between its Genentech subsidiary and a China biopharma. The deal was originally announced in August.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!